TY - JOUR T1 - SECOND ALLOGENEIC STEM CELL TRANSPLANTATION: A MORTALITY ANALYSIS JF - medRxiv DO - 10.1101/2020.07.21.20153684 SP - 2020.07.21.20153684 AU - Mustafa Alani AU - Jean Henri Bourhis Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/26/2020.07.21.20153684.abstract N2 - Second allogeneic stem cell transplantation was realized in 48 patients with myeloid and lymphoid neoplasms at Gustave Roussy institute since 1987. Overall survival rate was about 30 % with better outcome in acute myeloid leukemia cases. Non-relapse related mortality is overwhelming, especially in myelodysplasia patients and despite the fact that complete remission was obtained in their majority. Graft versus Host disease is very common after second transplantation with many grade III – IV cases and one death from severe pulmonary GvHD lesions. Reduced intensity conditioning is certainly less toxic and together with optimal GvHD and infectious disease management, Second SCT may be a reasonable therapeutic option and the only curative treatment for many hematological malignancies.Competing Interest StatementThe authors have declared no competing interest.Funding Statementno particular fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data was anonymized prior to utilization by ProMISe database management system. Authors only had access to anonymized data.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Yesresearch data is available in Gustave Roussy registryGvHDGraft versus Host DiseaseSCTStem Cell TransplantationEBMTEuropean Society for Blood and Marrow TransplantationPTLDPost-Transplantation Lymphoproliferative diseaseMDS/MPNMyelodysplastic syndrome / Myeloproliferative neoplasiaAMLAcute Myeloid LeukemiaALLAcute Lymphoid LeukemiaHLHodgkin LymphomaTCLT cell LymphomaSBLSmall cell LymphomaFLFollicular LymphomaDLBCLDiffuse large B cell LymphomaMMMultiple MyelomaRDRelated donorMUDMatched unrelated donorUCBUmbilical Cord BloodMACMyeloablative conditioningRICReduced Intensity conditioningCRComplete remissionPRPartial remissionSDStable diseasePDProgressive diseaseVODVeno-occlusive diseaseHFHeart FailureCMVCytomegalovirusEBVEpstein-Barr Virus ER -